Table 2.

Incidence of osteonecrosis of the jaw [10], [28], [7], [16], [17], [18], [19], [20].

	General population	Metastatic breast, prostate cancer	Multiple myeloma
Oral bisphosphonates	0.00038–0.06%	Single reports	Single reports
Pamidronate	n/a	0.5–1%	1–4%
Zoledronic acid	0.06%	1.2–2.9%	1–10%
Denosumab	0% in 3 years	2%	1.1%